Search Results - "Duboscq, C"

High variability in Factor IX one‐stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system by Duboscq, C., Sueldo, E., Rosa, C., Zirpoli, M., Ceresetto, J., Baques, A., Arias, M.

“…Introduction Haemophilia B (HB) is an X‐linked hereditary bleeding disorder characterized by coagulation factor IX (FIX) deficiency. To improve the quality of…”
Get full text

The fibrinogen prothrombin time‐derived method is not useful in patients anticoagulated with low molecular weight heparins or rivaroxaban by Duboscq, C., Martinuzzo, M. E., Ceresetto, J., Lopez, M., Barrera, L., Oyhamburu, J., Stemmelin, G.

“…Essentials Fibrinogen prothrombin time‐derived (FIBPT‐d) behavior in anticoagulated patients is under studied. FIBPT‐d method overestimates fibrinogen in…”
Get full text

False‐positive lupus anticoagulant results by DRVVT in the presence of rivaroxaban even at low plasma concentrations by Martinuzzo, M. E., Forastiero, R., Duboscq, C., Barrera, L. H., López, M. S., Ceresetto, J., Penchasky, D., Oyhamburu, J.

Get full text

EE132 Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina by Garay, OU, Guinazu, G, Adamczuk, YP, Duboscq, C

Get full text

PB1127 Performance of Different Pairs of APTTs with High and Low Sensitivity to Phospholipids to Diagnose Lupus Anticoagulant by Bertoncin, A., Duboscq, C., José, C., German, S.

Get full text

Plasminogen activator inhibitor-1 activity and 4G/5G polymorphism in hemodialysis by Trimarchi, H, Duboscq, C, Genoud, V, Lombi, F, Muryan, A, Young, P, Schwab, M, Castanon, M, Rodriguez-Reimundes, E, Forrester, M, Pereyra, H, Campolo-Girard, V, Seminario, O, Alonso, M, Kordich, L

“…Chronic insufficiency alters homeostasis, in part due to endothelial inflammation. Plasminogen activator inhibitor-1 (PAI-1) is increased in renal disease,…”
Get full text

Diferencias en la conclusión final de la búsqueda de anticoagulante lúpico en pacientes anticoagulados con antagonistas de la vitamina K by Lopez Romera, J, Ceresetto, J, Duboscq, C, Bossio, F, Stemmelin, G, Bertoncin, A

“…Resumen Introducción. La detección de anticoagulante lúpico (AL) en pacientes que reciben el tratamiento con antagonistas de la vitamina K (AVK) es todavía una…”
Get full text

Heparin cofactor II in diabetic patients by Duboscq, C, Quintana, I, Barros, J, Kordich, L

“…Levels of heparin cofactor II (HCII) activity and antigen and electrophoretic pattern were studied both in normal subjects and in type I diabetic patients with…”
Get more information

Aspectos diagnósticos, fenotipo y tratamiento de la deficiencia de FXI by Duboscq, C, Stemmelin, G, Bovari, S.M, Ceresetto, Jose

“…The bleeding disorder in patients with factor XI deficiency has presented practical and conceptual challenges for clinicians and basic scientists.In FXI…”
Get full text

Uso y limitaciones del dímero D en la exclusión del tromboembolismo venoso by Duboscq, C, Gálvez, K.M, Díaz Ríos, Lilian, Martinuzzo, Marta, Sua, L.F, Echenagucia, M, Garzón, A, Bottaro, F, Saavedra, J, Ramos, G, Ceresetto, J. M

“…D-dimer is a marker of thrombin and plasmin generation. The usefulness of D-dimer measurement as a negative predictive value in the exclusion of thromboembolic…”
Get full text

La maladie de Mondor : à propos de deux cas by Thiery, Gaëtan, Liard, O., Duboscq, JC

“…Les auteurs rapportent deux cas d'une maladie de Mondor après chirurgie de réduction mammaire. Cette pathologie rare et bénigne doit être connue de tout…”
Get full text

Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role by Rossi, E B, Duboscq, C L, Kordich, L C

“…Heparin Cofactor II (HCII) is a glycoprotein in human plasma which inactivates thrombin rapidly in the presence of dermatan sulfate. Inhibition occurs by…”
Get more information

IMPAIRED CLOT LYSIS BY rt-PA CATALYZED MINI-PLASMINOGEN ACTIVATION by Duboscq, Cristina, Genoud, Valeria, Parborell, M.Fernanda, Kordich, Lucía C.

“…The fibrinolytic system contains a proenzyme plasminogen (Plg) which is converted to plasmin (Plm) by the action of Plg activators. Physiological Plg…”
Get full text

Plasminogen: an important hemostatic parameter in septic patients by Duboscq, C, Quintana, I, Bassilotta, E, Bergonzelli, G E, Porterie, P, Sassetti, B, Haedo, A S, Wainsztein, N, Kruithof, E K, Kordich, L

“…Previously we observed in some but not all septic patients a low plasma concentration of plasminogen. To investigate prospectively whether plasma levels of…”
Get more information

Mondor's disease: about two cases by Thiery, Gaëtan, Liard, O, Duboscq, J C

“…The authors report two cases of Mondor's disease after mammoplasty reduction's surgery. This pathology rare and benign should be known by all surgeons, because…”
Get full text

Parotid calcinosis of the pseudo-tumoral type (author's transl) by Koulmann, M, Verdier, M, Duboscq, J C

“…An atypical feature of a further case of salivary calcinosis reported was its exclusively unilateral parotid site. The clinical appearance was that of a…”
Get more information

Treatment of noma by Thiery, G, Liard, O, Duboscq, J C

“…Noma is a disease specific to developing countries. Early antibiotic treatment can stop disease progression. Surviving patients may present disfigurement with…”
Get more information

René Le Fort, from Lille (1869-1951) by Pons, J, Duboscq, J C, Sadania, J B

Get more information

Noma or cancrum oris: etiopathogenic and nosologic aspects by Costini, B, Larroque, G, Duboscq, J C, Montandon, D

“…Noma is a gangrenous disease that usually begins in the mouth and is characterized by rapid necrotizing destruction of soft tissue and underlying bone. The…”
Get more information

Detattooing by Pasturel, A, Bellavoir, A, Duboscq, J C, Sonneck, J M

Get more information